Name | NecroX-5 |
Description | NecroX-5, a derivative of NecroX, exhibits anti-inflammatory and anti-cancer activities. NecroX-5 reduces intracellular calcium concentration. |
In vitro | NecroX-5 (10-40 μM) reduces mitochondrial ROS levels and inhibits AKT and breast cancer cell migration. NecroX-5 (10 μM) blocks Ca2+ influx and decreases intracellular calcium concentration in 4T1 cells[1]. In LPS-stimulated H9C2 cells, NecroX-5 (10 µM), effectively decreases the increased TGF-β1, pSmad2, TNF-α and the expression of Dcn[2]. |
In vivo | In TUBO-P2J tumour-bearing mice, NecroX-5 (2.5 mg/kg) inhibits the metastasis of breast cancer cell[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 153.0 mg/mL (236.9 mM ), Sonication is recommended.
|
Keywords | NecroX 5 | NecroX-5 | NecroX5 |
Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Butamben | Ethyl cinnamate | 1-Octanol | 1,2,4-Trihydroxybenzene | Otilonium bromide |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Ion Channel Targeted Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |